|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:nonsteroidal_anti-inflammatory_drug
|
|
gptkbp:approvalYear
|
1999
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
M01AH02
|
|
gptkbp:brand
|
gptkb:Vioxx
|
|
gptkbp:CASNumber
|
162011-90-7
|
|
gptkbp:chemicalFormula
|
C17H14O4S
|
|
gptkbp:discoveredBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:eliminationHalfLife
|
17 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:IUPACName
|
4-(4-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone
|
|
gptkbp:legalStatus
|
withdrawn
|
|
gptkbp:mechanismOfAction
|
gptkb:nonsteroidal_anti-inflammatory_drug
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
314.36 g/mol
|
|
gptkbp:retired
|
increased risk of cardiovascular events
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
heart attack
stroke
edema
hypertension
gastrointestinal upset
|
|
gptkbp:usedFor
|
osteoarthritis
pain relief
rheumatoid arthritis
dysmenorrhea
|
|
gptkbp:withdrawn
|
2004
|
|
gptkbp:bfsParent
|
gptkb:COX-2
gptkb:PTGS2
gptkb:Prostaglandin-endoperoxide_synthase_2
gptkb:PTGS2_gene
gptkb:Prostaglandin_G/H_synthase_2
gptkb:COX2
gptkb:Vioxx
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rofecoxib
|